Thornton, Emma; Vink, Robert. Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's Disease PLoS ONE, 2012; 7(4):e34138

Copyright: © 2012 Thornton, Vink. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PERMISSIONS

http://www.plosone.org/static/policies.action#copyright

3. Copyright and License Policies

Open access agreement. Upon submission of an article, its authors are asked to indicate their agreement to abide by an open access Creative Commons license (CC-BY). Under the terms of this license, authors retain ownership of the copyright of their articles. However, the license permits any user to download, print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and source of the work. The license ensures that the authors' article will be available as widely as possible and that the article can be included in any scientific archive.

Open access agreement: US government authors. Papers authored by one or more US government employees are not copyrighted, but are licensed under a Creative Commons public domain license (CC0), which allows unlimited distribution and reuse of the article for any lawful purpose. Authors should read about CC-BY or CC0 before submitting papers.

Archiving in PubMed Central. Upon publication, PLoS also deposits all articles in PubMed Central. This complies with the policies of funding agencies, such as the NIH in the USA, the Wellcome Trust, and the Research Councils in the UK, and the Deutsche Forschungsgemeinschaft in Germany, which request or require deposition of the published articles that they fund into publicly available databases.

http://www.plos.org/about/open-access/license/

LICENCE

The Public Library of Science (PLoS) applies the Creative Commons Attribution License (CC-BY) to works we publish (read the human-readable summary or the full license legal code). Under this license, authors retain ownership of the copyright for their content, but allow anyone to download, reuse, reprint, modify, distribute, and/or copy the content as long as the original authors and source are cited. No permission is required from the authors or the publishers.

Appropriate attribution can be provided by simply citing the original article (e.g., Kaltenbach LS et al. (2007) Huntington Interacting Proteins Are Genetic Modifiers of Neurodegeneration. PLoS Genet 3(5): e82. doi:10.1371/journal.pgen.0030082).

For any reuse or redistribution of a work, users must also make clear the license terms under which the work was published.

This broad license was developed to facilitate free access to, and unrestricted reuse of, original works of all types. Applying this standard license to your own work will ensure that it is freely and openly available in perpetuity.

If you have a question about the Creative Commons License please use this contact form and choose “General Questions.”

6 September 2012

http://hdl.handle.net/2440/73012
Treatment with a Substance P Receptor Antagonist Is Neuroprotective in the Intrastriatal 6-Hydroxydopamine Model of Early Parkinson’s Disease

Emma Thornton, Robert Vink
Adelaide Centre for Neuroscience Research, School of Medical Sciences, The University of Adelaide, Adelaide, South Australia

Abstract
Neuroinflammation and blood brain barrier (BBB) dysfunction have been implicated in the pathogenesis of Parkinson’s disease (PD). The neuropeptide substance P (SP) is an important mediator of both neuroinflammation and BBB dysfunction through its NK1 receptor in a process known as neurogenic inflammation. Increased SP content has previously been reported following 6-OHDA treatment in vitro, with the levels of SP correlating with cell death. The present study used an in vivo 6-OHDA lesion model to determine if dopaminergic degeneration was associated with increased SP in the substantia nigra and whether this degeneration could be prevented by using a SP, NK1 receptor antagonist. Unilateral, intrastriatal 6-OHDA lesioning was induced and SP (10 µg/2 µL) or the NK1 receptor antagonist L-333,060 (20 µg at 100 nM) administered immediately after the neurotoxin. Nigral SP content was then determined using immunohistochemical and ELISA methods, neuroinflammation and barrier integrity was assessed using Iba-1, ED-1, GFAP and albumin immunohistochemistry, while dopaminergic cell loss was assessed with tyrosine hydroxylase immunohistochemistry. Motor function in all animals was assessed using the rotarod task. Intrastriatal 6-OHDA lesioning produced an early and sustained increase in ipsilateral nigral SP content, along with a breakdown of the BBB and activation of microglia and astrocytes. Further exacerbation of SP levels accelerated disease progression, whereas NK1 receptor antagonist treatment protected dopaminergic neurons, preserved barrier integrity, reduced neuroinflammation and significantly improved motor function. We propose that neurogenic inflammation contributes to dopaminergic degeneration in early experimental PD and demonstrate that an NK1 receptor antagonist may represent a novel neuroprotective therapy.

Introduction
Parkinson’s disease (PD) is the second most common neurodegenerative disorder affecting approximately 1% of the world’s population over the age of 65 [1]. It is characterized by a progressive loss of dopaminergic neurons from the substantia nigra (SN), an integral part of the basal ganglia (BG). The BG is a group of nuclei that is primarily involved in the smooth execution of movement, and whose complex function requires that its two main signalling pathways be balanced. These pathways are kept in balance by the release of dopamine (DA) from dopaminergic neurons projecting from the SN to the striatum (caudaute nucleus and putamen). For proper function of the BG, a basal level of striatal DA release is required; therefore in PD, a loss of striatal DA causes motor symptoms such as bradykinesia, akinesia, rigidity and postural instability. Accordingly, current treatment for PD involves increasing striatal DA levels by either direct replacement with L-DOPA, by administering DA agonists or by reducing DA metabolism. However, these only provide symptomatic relief and do not target the cause of the dopaminergic cell loss. Moreover, L-DOPA is highly effective in reducing motor symptoms for the first 5 to 10 years of use, continued use produces motor complications like dyskinesia and motor fluctuations [2]. Importantly, the progressive nature of cell loss in PD provides a window of opportunity in which a neuroprotective therapy could be administered to slow down or halt the progression of the disease. Unfortunately no known therapy exists to date.

Inflammatory processes and blood brain barrier (BBB) dysfunction have been associated with dopaminergic cell loss in PD. Activation of CNS immune cells such as microglia is observed in all animal models of PD, and in the SN of PD patients both on PET scans and at post-mortem [3,4,5]. Activated microglia damage cells by releasing pro-inflammatory cytokines, reactive oxygen species (ROS), nitric oxide (NO) and excitatory factors. An astrocytic response has also been observed in animal models of PD [3,6], although the involvement of these cells in PD pathogenesis still remains controversial [7]. The loss of BBB integrity reported in PD is thought to also contribute to the progression of the disease [8,9]. The barrier of the SN is known to be weaker than in other brain regions and therefore can be easily disrupted [10]. Moreover, dopaminergic neurons seem particularly vulnerable to BBB dysfunction, since induction of barrier breakdown leads to increased expression of apoptotic markers in DA neurons but not in hippocampal neurons [11].

An important mediator of both inflammation and increased BBB permeability in the CNS is the neuropeptide, substance P (SP). SP belongs to the tachykinin family, is widely found...
throughout the central and peripheral nervous systems, and preferentially binds to the NK1 tachykinin receptor, which like SP, is broadly distributed throughout the body. Accordingly, SP is involved in a diverse range of functions including smooth muscle contraction, transmission of sensory information, and nociception, amongst others (reviewed by [12]). SP is found in particularly high levels in the SN. Here, SP binds to NK1 receptors expressed on dopaminergic neurons, where internalisation of the SP/NK1 complex causes excitation and the release of DA into the striatum [13]. However, DA can also potentiate the release of SP within the nigra by binding to its D1 receptor, located on striatal SP-containing medium spiny projection neurons [14]. Thus, SP and DA regulation is via a positive feedback mechanism.

Recently, 6-OHDA treatment of dopaminergic neurons in vivo produced an early and sustained increase in SP content, which significantly correlated with lactate dehydrogenase expression, a marker of cell death [15], suggesting that SP may play a role in dopaminergic cell. In the current study, we investigated whether SP may also be increased in vivo following induction of intrastratal 6-OHDA lesions, a model of early PD, thereby initiating DA cell death by facilitating inflammation and BBB dysfunction.

**Results**

Intrastriatal injections of 6-OHDA resulted in a progressive loss of TH positive neurons in the ipsilateral SN that was not apparent until day 7 post-lesion and was significant by day 14 (p<0.001; Figure 1A). By day 21, vehicle treated animals demonstrated further loss of these neurons. This loss was significantly exacerbated when SP was administrated immediately after the 6-OHDA (p<0.01). Conversely, treatment with the NK1 receptor antagonists, NAT and L-733,060, protected TH neurons, with these animals demonstrating a 28.5±5.8% and a 28.1±4.1% loss of neurons, respectively, compared to the 40.9±3.1% loss reported in vehicle treated animals.

The loss of ipsilateral TH positive nigral neurons produced a significant motor deficit as assessed by the rotarod task (Figure 1B). In contrast to sham animals who had normal motor function and could complete the 2 min task, vehicle treated animals were unable to learn the task and overall recorded a mean of 78.9±0.9 secs. SP treated animals displayed greater motor deficits as they performed only 69.8±1.1 secs on the rotarod task, whereas both NAT and L-733,060 treated animals performed significantly better than vehicle treated animals throughout the assessment period (p<0.05).

To determine the mechanism by which NK1 antagonism protected DA neurons and improved motor function, SP content, BBB integrity and neuroinflammation was assessed. Intrastriatal 6-OHDA lesions produced an early and sustained increase in SP content in the ipsilateral SN compared to the contralateral SN (Figure 2A-C). Vehicle treated animals had greater SP content, whereas animals treated with SP or an NK1 antagonist had comparable SP content to shams. SP content was also measured at day 3 and 7 using an ELISA assay (Figure 2D). Again, an increase in SP content was recorded in the ipsilateral striatum and SN, with a greater rise seen in the striatum at day 3 and within the SN at day 7. Thus the day at which SP was maximal differed in each technique. This is likely due to ELISA assessing the entire SN and some of the surrounding tissue compared to color deconvolution, which primarily included the pars compacta region of the SN.

6-OHDA intrastriatal lesions resulted in BBB breakdown and obvious albumin immunoreactivity in the ipsilateral nigra by day 7 post-lesion. Loss of barrier integrity was still apparent at day 21 as vehicle treated animals had marked albumin immunoreactivity (Figure 3). SP treated animals also demonstrated BBB dysfunction, however treatment with an NK1 antagonist preserved barrier integrity with both NAT and L-733,060 treated animals resembling sham animals.

Intrastriatal 6-OHDA lesions resulted in marked neuroinflammation (Figure 4 and 5). A small increase in Iba-1 positive reactive microglia was seen by day 3, and was maximal by day 14 at which point a significant increase in Iba-1 immunoreactive microglia was detected (p<0.01). Although the presence of ED-1 positive microglia was also maximal at day 14, the appearance of these cells was not seen until day 7 post-lesion. Vehicle treated animals had a significant increase in the number of both Iba-1 and ED-1 positive microglia compared to sham animals (p<0.01). SP treatment exacerbated the microglial response as these animals had a greater number of both Iba-1 and ED-1 immunoreactive microglia than vehicle treated animals, although this increase was not significant. Conversely, both NAT and a L-733,060 treated animals had an approximate 10% decrease in ED-1 immunoreactive microglia compared to vehicle treated animals. Despite this,
only the NAT treated animals had a smaller number of Iba-1 positive microglia. The presence of GFAP positive reactive astrocytes was similar to microglia. Maximal numbers of reactive astrocytes were recorded on day 14 post-lesion, with a highly significant increase still apparent in vehicle treated animals compared to sham animals \((p < 0.001)\). However, both SP and NK1 antagonist treatment resulted in a small decline in reactive astrocytes compared to vehicle treated animals, although a significantly greater number was still apparent compared to shams.

**Discussion**

In the current study, we demonstrate that intrastriatal 6-OHDA lesions result in elevated SP production within the ipsilateral SN that remained above sham levels for 21 days. The increased SP levels were associated with increased BBB permeability, microglial and astrocyte activation, increased dopaminergic cell death and profound motor deficits. Moreover, treatment with additional SP at the time of 6-OHDA administration accelerated the progression of the disease, with animals displaying profound motor deficits and exacerbated dopaminergic cell death. In contrast, blocking the effects of SP with administration of an NK1 antagonist preserved barrier integrity, reduced inflammatory processes, attenuated 6-OHDA induced cell death and resulted in a significant improvement in motor function. To the best of our knowledge, this is the first demonstration that increased SP may play a critical role in early dopaminergic degeneration.

Although a potential role for SP in PD has been previously suggested, unlike in the current study, this was on the basis of decreased SP content and NK1 receptors within the BG in both clinical [16,17,18,19,20,21] and experimental models of PD [22,23]. These reports of SP decline were in post-mortem PD tissue and in models that replicate the late stages of the disease. It is likely that the observed loss of SP under these conditions is a secondary effect of dopaminergic degeneration, due to the interruption to the positive feedback regulation between SP and DA. Indeed, a 90% decrease in striatal DA has reportedly been required to deplete SP content within the SN [19]. In this study, nigral SP content was only decreased in the SP treated animals, which had significantly greater dopaminergic neuronal loss than any other group.

There are several possible mechanisms to account for the increase in SP seen in this study. During early dopaminergic degeneration, DA production is upregulated from surviving neurons in an attempt to attenuate the loss of striatal DA [24]. As mentioned, in the nigrostriatal pathway of the BG, SP and DA production are modulated by a positive feedback mechanism, whereby each neurotransmitter can potentiate the release of the other. Thus an increase in DA turnover may facilitate a localized increase in nigral SP. Another possible source of SP is other BG nuclei such as the globus pallidus (GP), which is also involved in...
the regulation of DA neurons, in part through SP containing projections from the internal segment of the GP to the SN [25]. Furthermore, the increase in nigral reactive astrocytes seen following intrastriatal 6-OHDA lesions can account for increased SP, as they are also known to produce SP [26].

This increase in SP is significant given that SP induces neurogenic inflammation, a neurally elicited inflammatory response caused by injury or infection, and involving the release of calcitonin-gene related peptide (CGRP) and SP from primary sensory nerve fibers surrounding blood vessels [27]. CGRP, a potent vasodilator, increases blood flow whereas SP, by binding to NK1 receptors on perivascular tissue, induces plasma extravasation, BBB breakdown and often genesis of edema [28]. Although this process has been well described in peripheral nervous system tissue, it has only recently been described following injury to the brain [27,28,29,30]. Recently, a loss of BBB integrity has been implicated in the progression of PD [8,9,11].

SP induced breakdown of the BBB, as seen with albumin immunoreactivity, was noted in this study, with treatment with an NK1 antagonist preserving barrier integrity. Even a small breakdown in the BBB can be harmful to neurons by permitting an influx of peripheral immune cells, such as T-lymphocytes, blood borne macrophages and neutrophils into the brain. Peripheral immune cells also secrete pro-inflammatory cytokines, and once they enter the brain, they cannot only directly injure dopaminergic neurons, they can also activate resident microglia and astrocytes to indirectly contribute to cell loss. Indeed, CD4+ T-leukocytes have been implicated in MPTP induced DA cell death [31] and increased neutrophil infiltration has been associated with selective nigral dopaminergic degeneration in PD

Figure 3. Changes in albumin extravasation following intrastriatal 6-OHDA lesions. Compared to sham animals (A), vehicle (B) and SP (C) treated animals demonstrate albumin immunoreactivity in the ipsilateral SN at day 21, whereas both NAT (D) and L-733,060 (E) treated animals resemble shams. Color deconvolution (F) confirms these trends. Arrows denote albumin. Bar = 500 μm.

doi:10.1371/journal.pone.0034138.g003
lipids, proteins and DNA [38]. Indeed, ROS are thought to be major contributors to 6-OHDA-mediated cell death [39]. Notably, microglia express NK1 receptors and SP is considered to be a potent microglial activator [40,41,42].

In the current study, an increase in Iba-1 positive microglia was observed prior to TH neuronal loss, confirming that the appearance of activated microglia may proceed neurodegeneration [43]. Moreover, activation of microglia correlated with the degree of dopaminergic degeneration, as SP treated animals had the greatest loss of DA neurons and the most nigral Iba-1 and ED-1 immunoreactive microglia. Conversely, animals treated with the NK1 antagonists had less Iba-1 immunoreactive microglia and a small reduction in the number of ED-1 positive microglia. Thus, inhibition of microglial activation using the SP, NK1 receptor antagonists may have contributed to the protection of dopaminergic neurons.

Astrocytes also express the NK1 receptor [44], and once activated by SP, NF-κB translocates to the nucleus resulting in cytokine secretion [45]. An increase in GFAP positive reactive astrocytes was observed in the SN of all 6-OHDA groups. Reactive astrocytes may be beneficial by metabolizing excess cytosolic DA and through secretion of glial- and brain-derived neurotrophic factors and antioxidant enzymes [46]. Conversely, their secretion of pro-inflammatory cytokines may contribute to inflammatory processes and injury. In the current study, the effect astrocytes had on dopaminergic neurons is unclear as both SP and NK1 antagonist treated animals had a reduction in the number of these cells compared to vehicle treated animals. Nonetheless, due to SP’s ability to induce proinflammatory cytokine secretion from astrocytes, we suggest that the reduction in reactive astrocytes by NK1 antagonists was beneficial and contributed to the preservation of dopaminergic neurons.

NK1 antagonism may also both directly reduce excitotoxic damage to DA terminals and neurons, or indirectly reduce excitotoxic damage by protecting dopaminergic neurons through other means and thus reduce subsequent subthalamic nucleus (STN) overactivity. Due to the functional arrangement of the BG, decreased striatal DA causes overactivity of the STN. The STN uses glutamate to send excitatory signals to the GP and SN to modulate the burst firing of dopamine neurons [47]. With no inhibition of the STN, excess glutamate will be released within the SN to bind to glutamate receptors located on dopaminergic neurons causing excitotoxic damage, a major contributor of cell death in PD [48]. Moreover, NMDA-evoked striatal glutamate release requires the activation of striatal NK1 and DA receptors [49].

In conclusion, SP is increased in the intrastriatal 6-OHDA model of early PD. This elevation in SP levels may contribute to the demise of dopaminergic neurons by modulating CNS inflammatory processes including the activation of microglia and astrocytes, as well as facilitating increased DA turnover and free radical production. This is the first study to implicate SP induced neurogenic inflammation in BBB breakdown and dopaminergic cell death in experimental early PD. Thus, NK1 antagonists may represent a novel therapeutic agent that may slow down progression of PD and prevent functional deficits in early PD.

Materials and Methods

Ethics Statement

All experimental protocols were conducted according to the guidelines established by the National Health and Medical Research Council of Australia and were approved by the animal ethics committees of the University of Adelaide and SA Pathology (approval number 65/03).
Induction of PD

A total of 75 male, Sprague-Dawley rats weighing 250–300 g were group housed under a 12-hour light/dark cycle with access to food and water *ad libitum*. Animals were randomly assigned to sham (not lesioned) or 6-OHDA lesioning plus treatment with either an NK1 receptor antagonist (N-acetyl-L-tryptophan; NAT or L-733,060), SP, treatment vehicle (artificial CSF) or no treatment. The NK1 antagonist treated groups were administered either 2 μL of 50 nM NAT (Sigma) or 2 μL of 100 nM L-733,060 (Tocris) into the right lateral ventricle (stereotaxic co-ordinates: AP: +0.6 mm, ML: 1.5 mm relative to bregma and V: 3.5 mm from dura [50]) immediately following intrastriatal 6-hydroxydopamine-bromide (6-OHDA; Sigma) injections. The SP treated group was administered 2 μL of SP salt-acetate (5 mg/mL; Sigma) as described above for the NK1 antagonist groups. The NK1 receptor antagonist and SP doses were chosen on the basis of their known physiological effects in the nigra [51,52]. The vehicle treated group received equal volume of vehicle (artificial CSF). Shams underwent the surgical procedure only without administration of the 6-OHDA.

The intrastriatal, 6-OHDA model of early PD has been previously described in detail elsewhere [53]. Briefly, animals were anesthetized with 3% Isoflurane (1.5 L/min O2), placed onto a stereotaxic device and two 0.7 mm burr holes then made over the right striatum at stereotaxic coordinates (1) AP: 0.5 mm, ML: 2.5 mm, and (2) AP: −0.3 mm, ML: 4.2 mm relative to bregma [50,53]. Two μL of 6-OHDA (5 μg/μL) was then injected into the right striatum at 5.0 mm ventral from the dura in each of the two burr holes at a rate of 0.5 μL/min, with the needle then left in place for 2 min before being slowly retracted. Body temperature was maintained with a thermostatically controlled heating pad throughout the surgical procedures.

Motor Outcome

Following induction of PD, animals were assessed for motor deficits on an accelerating rotarod. The rotarod is a sensitive test of motor deficits by testing general motor function including co-ordination and balance, and tests sensorimotor learning deficits in early stage PD [54]. The rotarod task has been described in detail elsewhere [55]. In this study, animals were not pre-trained but were tested at the same time each morning on days 3, 7, 10, 14, 17 and 21 post-lesion.

Assessment of substance P, blood brain barrier and inflammation using immunohistochemistry

Following a predetermined survival period, animals were anesthetized with 5% Isoflurane, venously administered Heparin (5000 IU/mL) and transcardially perfused with 10% buffered formalin. The brain was cut into consecutive 2 mm coronal slices, processed and embedded in paraffin. The level containing the SN was cut into serial 5 μm sections that were processed as follows. Dopaminergic neurons were observed with tyrosine hydroxylase (TH) immunoreactivity (Chemicon; 1:8000; citrate retrieval). Nigral SP protein content was determined using SP immunoreactivity (Santa Cruz; 1:2000; EDTA retrieval). Iba-1 immunoreactivity (Wako; 1:5000; citrate retrieval) and ED-1 immunoreactivity (AbD Serotec; 1:400; citrate retrieval) was used to assess reactive and activated microglia. GFAP immunoreactivity (Dako;...
1:40000; citrate retrieval) assessed reactive astrocytes and BBB breakdown was observed using albumin immunoreactivity (Cooper Biomedical; 1:20000; no retrieval).

All sections underwent a similar immunohistochemical procedure, with all antibodies incubated at room temperature and PBS washes applied between each antibody. Briefly, sections were de-waxed, dehydrated and placed in methanol with 30% hydrogen peroxide. Specified microwave antigen retrieval was performed as required and sections incubated for 45 min in 3% normal horse serum. Primary antibody was added overnight before specific biotinylated secondary antibody (Vector, 1:250) was added for 30 mins. Tertiary streptavidin peroxidase conjugate (SPC; Pierce, 1:1000) was added for 1 hour and the immuno-complex visualised using 3,3’-diaminobenzidine (DAB; Sigma) as a chromogen in the peroxidase reaction.

TH immunoreactive neurons were counted in the ipsilateral and contralateral SN at 20× magnification. The number of ipsilateral TH positive neurons was compared to contralateral neurons (internal control) to determine the percentage of ipsilateral dopaminergic cell loss. Iba-1 positive microglia, with intense cytoplasmic immunoreactivity and shortened processes, along with ED-1 immunoreactive microglia were counted in the ipsilateral SN at 20× magnification. The area of the SN was also determined to allow the number of reactive/activated microglia per mm² to be determined. The number of reactive astrocytes was assessed in a similar manner to microglia with astrocytes counted that had upregulated GFAP immunoreactivity and shortened processes.

To non-subjectively estimate SP protein content and BBB integrity within the ipsilateral SN, all immunohistochemistry was subject to automated, color deconvolution analysis [54]. Briefly, SP and albumin immunohistochemical sections were scanned using a Nanozoomer (Hamamatsu) before jpeg images at 20× magnification for SP and 10× magnification for albumin were exported from both the ipsilateral and contralateral SN. These jpeg images underwent color deconvolution, which separates the DAB color vector image from the hematoxylin color vector image. The amount of DAB precipitate (antigen content) was estimated using the histogram analysis of the DAB color image and a mathematical formula, which determined the percentage of weighted DAB (DABwt%) in the image. The weighting of the DAB is critical as it eliminates non-specific background staining whilst amplifying positive staining, and also gives a semi-quantitative estimation of intensity upon which statistical analyses can be performed [56]. As SP immunoreactivity can differ from batch to batch due to minor technical variations, each image was corrected using an internal control (interhemispheric leptome-ninges), which is affected only by technique and not induction of PD. This allows an accurate assessment of the amount of SP content in the SN. Albumin immunoreactivity is unaffected between batches, however the amount of adjusted DABwt% within the ipsilateral SN was compared to contralateral SN (internal control).

**Semi-quantification of substance P using ELISA**

At day 3 or 7 following intrastriatal 6-OHDA lesions, animals were re-anaesthetized with 5% Isoflurane (1.5 L/min O2), decapitated and their brain removed. The striatum and midbrain were rapidly dissected out, the hemispheres divided and the cortex removed from the surrounding structures. Each brain region was weighed then homogenised in buffer containing 0.01% TritonX-100, DL-dithiothreitol and protease inhibitors pepstatin A, aproti-nin, leupeptin and phenylmethanesulfonyl fluoride. Protein content of the samples was estimated using a Biorad protein estimation assay, with samples diluted with tris-buffered saline (TBS) to 100 ng protein per 100 µL sample. An ELISA assay was used to determine the level of SP in the striatum and SN. Brain homogenate samples and control blank wells were loaded in triplicate and left overnight at 4°C. Blocking agent was added for 1 hour before 100 µL of SP primary antibody (Chemicon; 1:1000) was incubated at 37°C for at least 1 hr. 100 µL of secondary anti-rabbit horseradish peroxidase conjugate (Rockford, 1:500) antibody was incubated for 1 hr at 37°C before 100 µL/well of liquid substrate system 3,3’-5,5’-tetramethylbenzidine (Sigma) used to visualize SP content. TBS washes (3×) occurred between each step.

**Statistical Analysis**

All data was analysed using an Analysis of Variance (ANOVA) followed by Neuman-Keuls multiple comparison posthoc tests (GraphPad Prism). Data is expressed as mean ± standard error of the mean (SEM).

**Author Contributions**

Conceived and designed the experiments: ET RV. Performed the experiments: ET. Analyzed the data: ET RV. Contributed reagents/materials/analysis tools: RV. Wrote the paper: ET RV.

**References**

1. Alves G, Forsaa EB, Pedersen KF, Dreetz Gjerstad M, Larsen JP (2008) Epidemiology of Parkinson’s disease. J Neurol 255: 18–32.
2. Chen L-W, Yung KKL, Chan YS (2004) Neuropeptide peptides and neuropeptide receptors as potential therapeutic intervention targets of basal ganglia in the prevention and treatment of Parkinson’s disease. Current Drug Targets 5: 1–10.
3. Depino AM, Earl C, Kaczmarczyk E, Ferrari C, Besedovsky H, et al. (2003) Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson’s disease. Eur J Neurosci 18: 2731–2742.
4. McGeer PL, McGeer EG (2000) Glial reactions in Parkinson’s disease. Mov Disord 23: 474–483.
5. Mosley RL, Benner EJ, Kadiu I, Thomas M, Boska MD, et al. (2006) Neuroinflammation, oxidative stress and the pathogenesis of Parkinson’s disease. Clin Neurosci Res 6: 261–201.
6. Takagi S, Hayakawa N, Kimoto H, Kato H, Araki T (2007) Damage to oligodendrocytes in the striatum after MPTP neurotoxicity in mice. J Neural Transm 114: 1533–1557.
7. Chung YC, Ko HW, Bok E, Park ES, Huh SH, et al. (2008) Decreased blood-brain barrier Pglycoprotein function in the progression of Parkinson’s disease, PSP and MSA. J Neural Transm 115: 1001–1009.
8. Bartels AL, Willemsen AT, Kortekaas R, de Jong BM, de Vries R, et al. (2008) Decreased blood-brain barrier Pglycoprotein function in the progression of Parkinson’s disease. J Neural Transm 115: 1001–1009.
9. Kortekaas R, Leenders KL, van Oostrom JC, Vaalburg W, Bart J, et al. (2005) Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 57: 176–179.
10. Jones ID (2008) Self-amplification of nigral degeneration in Parkinson’s disease: a hypothesis. Int J Neurosci 118: 1763–1780.
11. Rite I, Machado A, Cano J, Venero JL (2007) Blood-brain barrier disruption modulates nigral dopaminergic neurons. J Neurochem 101: 1567–1582.
12. Harrison S, Greppotti P (2001) Review: Substance P. The International J Biochem Cell Biol 33: 555–576.
13. Levesque M, Wallman MJ, Parent R, Sik A, Parent A (2007) Neurokinin-1 and neurokinin-3 receptors in primate substantia nigra. Neurosci Res 57: 362–371.
14. Reid MS, Herrera-Marschitz M, Hokfelt T, Lindefors N, Persson H, et al. (1990) Striatonigral GABA, dynorphin, substance P and neurokinin A modulation of nigrostriatal dopamine release: evidence for direct regulatory mechanisms. Exp Brain Res 82: 293–303.
15. Thorsen E, Tjon TT, Viok R (2010) A substance P mediated pathway contributes to 6-hydroxydopamine induced cell death. Neurosci Lett 481: 64–67.
16. De Ceballos ML, Lopez-Lozano JJ (1999) Subgroups of parkinsonian patients differentiated by pertidergic immunostaining of caudate nuchae biopsies. Peptides 20: 249–257.
17. Maulaigue A, Javye-Ajig F, LeGrand JC, Ajid J, Ceselin F (1983) Decrease of substance P-like immunoreactivity in the substantia nigra and pallidum of parkinsonian brains. Brain Res 268: 167–170.

18. Nisbet AP, Foster OJ, Kingsbury A, Eve DJ, Daniel SE, et al. (1995) Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson’s disease. Neuroscience 66: 361–376.

19. Swam SP (1991) Dopamine dependent decrease in enkephalin and substance P levels in basal ganglia regions of postmortem parkinsonian brains. Neuropeptides 18: 201–207.

20. Tenovuo O, Rinne UK, Viljanen MK (1984) Substance P immunoreactivity in the post-mortem parkinsonian brain. Brain Res 303: 113–116.

21. Fernandez A, de Goballos ML, Jenner P, Marodon CD (1994) Neurotensin, substance P, delta and mu opioid receptors are decreased in basal ganglia of Parkinson’s disease patients. Neuroscience 61: 73–79.

22. Bannom MJ, Brownschide LA, Tian Y, Whitty CJ, Poosch MS, et al. (1995) Neurokinin-5 receptors modulate dopamine cell function and alter the effects of 6-hydroxydopamine. Brain Res 693: 19–24.

23. Schwarting RK, Huston JP (1996) Unilateral 6-hydroxydopamine lesions of substantia nigra pars compacta and cortex. Glia 56: 1039–1047.

24. Deumens R, Blokland A, Prickaerts J (2002) Modeling Parkinson’s disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 175: 303–324.

25. Brevard MD, Smith AD, Bolam JP (1996) The substantia nigra as a site of synaptic integration of functionally diverse information arising from the ventral pallidum and the globus pallidus in the rat. Neuroscience 75: 5–12.

26. Liu RC (1995) Reactive astrocytes express substance-P immunoreactivity in the adult forebrain after injury. Neuroreport 7: 310–312.

27. Nimmo AJ, Cernak I, Heath DL, Hu X, Bennett CJ, et al. (2004) Neurogenic inflammation is associated with development of edema and functional deficits following traumatic brain injury in rats. Neuropeptides 38: 40–47.

28. Vink R, van den Heuvel C (2010) Substance P antagonists as a therapeutic approach to improving outcome following traumatic brain injury. Neurotherapeutics 7: 74–80.

29. Turner RJ, Helms SC, Thornton E, Vink R (2011) A substance P antagonist improves outcome when administered 4 hours after onset of reversible cerebral ischemia. Brain Res 1393: 84–90.

30. Donkin JN, Nimmo AJ, Cernak I, Blumbergs PC, Vink R (2009) Substance P is associated with the development of brain edema and functional deficits after traumatic brain injury. J Cereb Blood Flow Metab 29: 1380–1390.

31. Brochard V, Combadiere B, Prigent A, Perrin A, et al. (1999) Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson’s disease. Neuroscience 66: 361–376.

32. Schwarting RK, Huston JP (1996) Unilateral 6-hydroxydopamine lesions of substantia nigra pars compacta and cortex. Glia 56: 1039–1047.

33. Carson MJ, Thrash JC, Walters B (2006) The cellular response in neuroinflammation: The role of leukocytes, microglia and astrocytes in neuronal death and survival. Clin Neurosci Res 6: 237–245.

34. Gao HM, Jiang J, Wilson B, Zang W, Hong JS, et al. (2002) Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons relevance to Parkinson’s disease. J Neurochem 81: 1295–1297.

35. Trümper P, Schulz JB (2004) Cellular pathology of Parkinson’s disease: astrocytes, microglia and inflammation. Cell Tissue Res 318: 149–161.

36. Liu B, Hong JS (2003) Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 304: 1–7.

37. Rock RB, Peterson PK (2006) Microglia as a pharmacological target in infectious and inflammatory diseases of the brain. J Neuroimmune Pharmacol 1: 117–126.

38. Shults CW (2006) Mitochondrial dysfunction and possible treatments in Parkinson’s disease:a review. Mitochondrion 6: 641–648.

39. Blum D, Torch S, Lamberg N, Nissos M, Benabid AL, et al. (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson’s disease. Prog Neurobiol 65: 155–172.

40. Chauhan VS, Sorka DG, Jr., Gray DL, Best KL, Marriott I (2008) Neurogenic exacerbation of microglial and astrocyte responses to Neisseria meningitidis and Borrelia burgdorferi. J Immunol 180: 8241–8249.

41. Marriott I (2004) The role of tachykinins in central nervous system inflammatory responses. Front Biosci 9: 2153–2163.

42. Block ML, Li G, Qin L, Wu X, Pei Z, et al. (2006) Potent regulation of microglia-derived oxidative stress and dopaminergic neuron survival: substance P vs. dynorphin. Faseb J 20: 251–258.

43. Weijera M, Siikora B, Sobow T, Liberski PP (2005) Microglial cells in neurodegenerative disorders. Folia Neuropathol 43: 311–321.

44. Maurya PW, Johnson DJ, Bohmer CG, Catton MD, Vinters HV, et al. (1989) Substance P receptor binding sites are expressed by glia in vivo after neuronal injury. Proc Natl Acad Sci USA 86: 5193–5197.

45. Brahmunachi S, Fung YK, Pahan K (2006) Induction of glial fibrillary acidic protein expression in astrocytes by nitric oxide. J Neurosci 26: 4930–4939.

46. Hirsch EC (2000) Glial cells and Parkinson’s disease. J Neuroiol 247 Suppl 2: II56–62.

47. Rodriguez MC, Oheoo JA, Olanow C (1998) Subthalamic nucleus-mediated excitotoxicity in Parkinson’s disease: a target for neuroprotection. Ann Neurol 44: S178–188.

48. Beal MF (1992) Mechanisms of excitotoxicity in neurologic disease. Faseb J 6: 3338–3344.

49. Maffei A, Manzalini M, Fantin M, BianchiC, Della Corte L, et al. (2005) Striatal glutamate release evoked in vivo by NMDA is dependent upon ongoing neuronal activity in the substantia nigra, endogenous striatal substance P and dopamine. J Neurochem 93: 195–203.

50. Pinto G, Watson C (1994) The Rat Brain Stereotaxic Coordinates. San Diego: Academic Press.

51. Bishop C, Walker PD (2004) Intranigral antagonism of neurokinin 1 and 3 receptors reduces intrastriatal dopamine DH receptor-stimulated locomotion in the rat. Brain Res 1023: 126–133.

52. Ukai M, Mori E, Kameyama T (1995) Effects of centrally administered neuropeptides on discriminative stimulus properties of cocaine in the rat. Pharmacol Biochem Behav 51: S178–188.

53. Lee CS, Sauer H, Bjorklund A (1996) Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat. Neuroscience 72: 641–653.

54. Ogura T, Ogata M, Akia H, Jitsuki S, Akiba Y, et al. (2005) Impaired acquisition of skilled behavior in rotated task by moderate depletion of striatal dopamine in a pre-symptomatic stage model of Parkinson’s disease. Neurosci Res 51: 299–308.

55. Hamn RJ, Pike BR, O’Dell DM, Lyeth BG, Jenkins LW (1994) The rotated test: an evaluation of its effectiveness in assessing motor deficits following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat. Neuroscience 72: 641–653.